Tyr-Gly compositions useful in increasing immune response
AssigneeImreg, Inc.
InventorA. Arthur Gottlieb
Life of this patent
Estimating the term…
Abstract
Compositions for delaying the progression from AIDS to ARC, and for alleviating symptoms of AIDS and ARC are disclosed together with clinical results of use of such compositions in clinical trials with of actual human patients suffering from these diseases. The compositions are based on a Tyr-Gly amino acid residue sequence. Typical dosage amounts are in the range of femtomoles/kg of body weight.
Claims28
A pharmaceutical composition comprising a pharmaceutically acceptable inert carrier and an effective dosage amount of YG Product, essentially free of endotoxin and pyrogen.
A pharmaceutical composition comprising a pharmaceutically acceptable inert carrier and an effective dosage amount of inhibited YG product.
A pharmaceutical composition comprising a pharmaceutically acceptable inert carrier and an effective dosage amount of expanded YG product.
A pharmaceutical composition comprising a pharmaceutically acceptable inert carrier and a predetermined amount of an artificial polypeptide, said polypeptide being one which metabolizes to YG as a result of the action of at least one endogenous human enzyme, and said predetermined amount being sufficient to provide said YG in an effective dosage amount.
A pharmaceutical composition comprising an amount of Tyr-gly dissolved or suspended in a pharmaceutically acceptable carrier suitable for injection, said amount being effective for stimulating the human immune system and said composition being substantially free of pyrogens and endotoxins.
A pharmaceutical composition comprising Tyr-Gly, essentially free of endotoxin and pyrogen, and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising an amount of Beta-1.13 that is effective for stimulating the human immune system, and dissolved or suspended in a pharmaceutically acceptable carrier suitable for injection, said composition being substantially free of pyrogen and endotoxin.
A pharmaceutical composition comprising an amount of at lest one of the following amplifiers--Beta-1.0, Beta-1.1, Beta-1.11, Beta-1.13--dissolved or suspended in a pharmaceutically acceptable carrier suitable for injection, wherein said amount of amplifier is effective for stimulating the human immune system and wherein said composition is substantially free of pyrogen and endotoxin.
In a vaccinal composition comprising a carrier and a vaccine-dosage amount of a disease-associated antigen or pathogen known not to provoke more than a negligible cell-mediated immune-system response when a person's immune system is challenged therewith, the improvement consisting of:
- a YG-dosage amount of YG product mixed with, or chemically linked to, said antigen or pathogen, said YG-dosage amount being sufficient to provoke more than a negligible cell-mediated immune-system response when a persons's immune system is challenged with said vaccine-dosage amount of antigen or pathogen in the presence of said YG-dosage amount of YG-material.
Dependencies are inferred from the claim text.